Higa GM et al. |
Biological considerations and clinical applications of new HER2-targeted agents. |
2010 |
Expert Rev Anticancer Ther |
pmid:20836684
|
Cho WC and Roukos DH |
Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets. |
2013 |
Expert Rev Anticancer Ther |
pmid:23259420
|
Bergamini A et al. |
Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer. |
2016 |
Expert Opin Investig Drugs |
pmid:27797594
|
Van den Mooter T et al. |
Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer. |
2015 |
Expert Opin Biol Ther |
pmid:25865453
|
Dirix LY et al. |
Trastuzumab emtansine in breast cancer. |
2013 |
Expert Opin Biol Ther |
pmid:23477731
|
Suwanborirux K et al. |
Ansamitocin P-3, a maytansinoid, from Claopodium crispifolium and Anomodon attenuatus or associated actinomycetes. |
1990 |
Experientia |
pmid:2298279
|
Schrek R and Stefani SS |
Toxicity of microtubular drugs to leukemic lymphocytes. |
1981 |
Exp. Mol. Pathol. |
pmid:7238845
|
Schatten G and Schatten H |
Effects of motility inhibitors during sea urchin fertilization: microfilament inhibitors prevent sperm incorporation and restructuring of fertilized egg cortex, whereas microtubule inhibitors prevent pronuclear migrations. |
1981 |
Exp. Cell Res. |
pmid:7308293
|
Thery JC et al. |
Resistance to human epidermal growth factor receptor type 2-targeted therapies. |
2014 |
Eur. J. Cancer |
pmid:24462377
|
Cruz-Monserrate Z et al. |
Dolastatin 15 binds in the vinca domain of tubulin as demonstrated by Hummel-Dreyer chromatography. |
2003 |
Eur. J. Biochem. |
pmid:12950266
|
Kolodych S et al. |
Development and evaluation of β-galactosidase-sensitive antibody-drug conjugates. |
2017 |
Eur J Med Chem |
pmid:28818506
|
Pode-Shakked N et al. |
The isolation and characterization of renal cancer initiating cells from human Wilms' tumour xenografts unveils new therapeutic targets. |
2013 |
EMBO Mol Med |
pmid:23239665
|
Haddley K |
Trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer. |
2013 |
Drugs Today |
pmid:24308017
|
Singh JC and Lichtman SM |
Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients. |
2015 |
Drugs Aging |
pmid:26645293
|
Dhillon S |
Trastuzumab emtansine: a review of its use in patients with HER2-positive advanced breast cancer previously treated with trastuzumab-based therapy. |
2014 |
Drugs |
pmid:24659374
|
Ballantyne A and Dhillon S |
Trastuzumab emtansine: first global approval. |
2013 |
Drugs |
pmid:23620199
|
Walles M et al. |
New Insights in Tissue Distribution, Metabolism, and Excretion of [3H]-Labeled Antibody Maytansinoid Conjugates in Female Tumor-Bearing Nude Rats. |
2016 |
Drug Metab. Dispos. |
pmid:27122302
|
Davis JA et al. |
In vitro characterization of the drug-drug interaction potential of catabolites of antibody-maytansinoid conjugates. |
2012 |
Drug Metab. Dispos. |
pmid:22752008
|
Shen BQ et al. |
Non-Clinical Disposition and Metabolism of DM1, a Component of Trastuzumab Emtansine (T-DM1), in Sprague Dawley Rats. |
2015 |
Drug Metab Lett |
pmid:26031461
|
Zhang J et al. |
Safety and efficacy of the addition of pertuzumab to T-DM1 ± taxane in patients with HER2-positive, locally advanced or metastatic breast cancer: a pooled analysis. |
2017 |
Drug Des Devel Ther |
pmid:29180848
|
Edwards A et al. |
Combinatorial effect of maytansinol and radiation in Drosophila and human cancer cells. |
2011 |
Dis Model Mech |
pmid:21504911
|
Yang H et al. |
Megakaryocyte lineage-specific class VI β-tubulin suppresses microtubule dynamics, fragments microtubules, and blocks cell division. |
2011 |
Cytoskeleton (Hoboken) |
pmid:21309084
|
Kim M et al. |
Updates on the treatment of human epidermal growth factor receptor type 2-positive breast cancer. |
2014 |
Curr. Opin. Obstet. Gynecol. |
pmid:24335887
|
Konecny GE |
Emerging strategies for the dual inhibition of HER2-positive breast cancer. |
2013 |
Curr. Opin. Obstet. Gynecol. |
pmid:23241641
|
Niculescu-Duvaz I |
Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer. |
2010 |
Curr. Opin. Mol. Ther. |
pmid:20521224
|
Smith S |
Technology evaluation: C242-DM1, ImmunoGen Inc. |
2001 |
Curr. Opin. Mol. Ther. |
pmid:11338934
|
Smith SV |
Technology evaluation: huN901-DM1, ImmunoGen. |
2005 |
Curr. Opin. Mol. Ther. |
pmid:16121706
|
Smith SV |
Technology evaluation: cantuzumab mertansine, ImmunoGen. |
2004 |
Curr. Opin. Mol. Ther. |
pmid:15663331
|
de Goeij BE and Lambert JM |
New developments for antibody-drug conjugate-based therapeutic approaches. |
2016 |
Curr. Opin. Immunol. |
pmid:26963132
|
Lu D et al. |
Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer. |
2012 |
Curr. Drug Metab. |
pmid:22475266
|
Shen BQ et al. |
Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism. |
2012 |
Curr. Drug Metab. |
pmid:22475269
|
Tumey LN and Han S |
ADME Considerations for the Development of Biopharmaceutical Conjugates Using Cleavable Linkers. |
2017 |
Curr Top Med Chem |
pmid:29357803
|
Nguyen-Ngoc T and Raymond E |
Reinvention of chemotherapy: drug conjugates and nanoparticles. |
2015 |
Curr Opin Oncol |
pmid:25783982
|
Mathew J and Perez EA |
Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review. |
2011 |
Curr Opin Oncol |
pmid:21986845
|
Boyraz B et al. |
Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. |
2013 |
Curr Med Res Opin |
pmid:23402224
|
MartÃnez MT et al. |
Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature. |
2016 |
Crit. Rev. Oncol. Hematol. |
pmid:26318092
|
Mustacchi G et al. |
HER2-positive metastatic breast cancer: a changing scenario. |
2015 |
Crit. Rev. Oncol. Hematol. |
pmid:25748080
|
Tsuda M et al. |
Abnormal Corneal Lesions Induced by Trastuzumab Emtansine: An Antibody-Drug Conjugate for Breast Cancer. |
2016 |
Cornea |
pmid:27149538
|
Chudasama VL et al. |
Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer. |
2012 |
Clin. Pharmacol. Ther. |
pmid:22968044
|
Wang J et al. |
Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer. |
2014 |
Clin. Pharmacol. Ther. |
pmid:24488143
|
Garzone PD and Atkinson AJ |
In search of physiologically based distribution volume estimates for macromolecules. |
2012 |
Clin. Pharmacol. Ther. |
pmid:22992670
|
Nicoletti R et al. |
T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2. |
2015 |
Clin. Exp. Metastasis |
pmid:25398397
|
Bartsch R et al. |
Activity of T-DM1 in Her2-positive breast cancer brain metastases. |
2015 |
Clin. Exp. Metastasis |
pmid:26303828
|
Nguyen M et al. |
Preclinical Efficacy and Safety Assessment of an Antibody-Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma. |
2015 |
Clin. Cancer Res. |
pmid:26240273
|
Ribrag V et al. |
A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. |
2014 |
Clin. Cancer Res. |
pmid:24132920
|
Krop I and Winer EP |
Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. |
2014 |
Clin. Cancer Res. |
pmid:24135146
|
Uppal H et al. |
Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1). |
2015 |
Clin. Cancer Res. |
pmid:25370470
|
Menderes G et al. |
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. |
2017 |
Clin. Cancer Res. |
pmid:28679774
|
Feng L et al. |
Efficacy of anti-RON antibody Zt/g4-drug maytansinoid conjugation (Anti-RON ADC) as a novel therapeutics for targeted colorectal cancer therapy. |
2014 |
Clin. Cancer Res. |
pmid:25294907
|
Amiri-Kordestani L et al. |
FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. |
2014 |
Clin. Cancer Res. |
pmid:24879797
|
Sabbaghi M et al. |
Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer. |
2017 |
Clin. Cancer Res. |
pmid:28821558
|
Mercogliano MF et al. |
TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer. |
2017 |
Clin. Cancer Res. |
pmid:27698002
|
Ogitani Y et al. |
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. |
2016 |
Clin. Cancer Res. |
pmid:27026201
|
Baselga J et al. |
Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer. |
2016 |
Clin. Cancer Res. |
pmid:26920887
|
Helft PR et al. |
A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. |
2004 |
Clin. Cancer Res. |
pmid:15240523
|
Junutula JR et al. |
Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. |
2010 |
Clin. Cancer Res. |
pmid:20805300
|
Ikeda H et al. |
The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. |
2009 |
Clin. Cancer Res. |
pmid:19509164
|
Al-Katib AM et al. |
Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma. |
2009 |
Clin. Cancer Res. |
pmid:19509168
|
Tijink BM et al. |
A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. |
2006 |
Clin. Cancer Res. |
pmid:17062682
|
Ostermann E et al. |
Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. |
2008 |
Clin. Cancer Res. |
pmid:18628473
|
LoRusso PM et al. |
Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. |
2011 |
Clin. Cancer Res. |
pmid:22003071
|
Blanc V et al. |
SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies. |
2011 |
Clin. Cancer Res. |
pmid:22003072
|
Carol H et al. |
The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia. |
2013 |
Clin. Cancer Res. |
pmid:23426279
|
Kalsi R et al. |
Brain metastasis and response to ado-trastuzumab emtansine: a case report and literature review. |
2015 |
Clin. Breast Cancer |
pmid:25454740
|
Li C et al. |
A Phase I Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function. |
2017 |
Clin Pharmacokinet |
pmid:27995530
|
Lu D et al. |
An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer. |
2013 |
Clin Pharmacokinet |
pmid:23553425
|
Kantarjian HM et al. |
A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. |
2016 |
Clin Lymphoma Myeloma Leuk |
pmid:26775883
|
Ohashi K et al. |
Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non-Small-Cell Lung Cancer: Study Protocol. |
2017 |
Clin Lung Cancer |
pmid:27497829
|
Socinski MA et al. |
Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease. |
2017 |
Clin Lung Cancer |
pmid:28341109
|
Bourdeanu L and Luu T |
Nursing perspectives on trastuzumab emtansine for the treatment of metastatic breast cancer. |
2013 |
Clin J Oncol Nurs |
pmid:24080060
|
Piwko C et al. |
Safety Profile and Costs of Related Adverse Events of Trastuzumab Emtansine for the Treatment of HER2-Positive Locally Advanced or Metastatic Breast Cancer Compared to Capecitabine Plus Lapatinib from the Perspective of the Canadian Health-Care System. |
2015 |
Clin Drug Investig |
pmid:26123628
|
Bander NH et al. |
Antibody-drug conjugate technology development for hematologic disorders. |
2012 |
Clin Adv Hematol Oncol |
pmid:23072775
|
Gligorov J et al. |
Emilia: use cunning to survive cancer. |
2018 |
Chin Clin Oncol |
pmid:29307196
|
Ricci F and Le Tourneau C |
Trastuzumab emtansine in HER2-positive metastatic breast cancer: what is the best sequence? |
2018 |
Chin Clin Oncol |
pmid:29156892
|
Bertholjotti I |
[Antibody-drug conjugate--a new age for personalized cancer treatment]. |
2011 |
Chimia (Aarau) |
pmid:22026193
|
Kwon Y et al. |
Telangiectasia and Pulmonary Arterial Hypertension Following Treatment With Trastuzumab Emtansine: A Case Report. |
2016 |
Chest |
pmid:27055712
|
Seidel K et al. |
Synthesis of Magnetic-Nanoparticle/Ansamitocin Conjugates-Inductive Heating Leads to Decreased Cell Proliferation In Vitro and Attenuation Of Tumour Growth In Vivo. |
2017 |
Chemistry |
pmid:28585348
|
Wang LL et al. |
A Bio-Chemosynthetic Approach to Superparamagnetic Iron Oxide-Ansamitocin Conjugates for Use in Magnetic Drug Targeting. |
2017 |
Chemistry |
pmid:27935144
|
Mancuso L et al. |
Preparation of thermocleavable conjugates based on ansamitocin and superparamagnetic nanostructured particles by a chemobiosynthetic approach. |
2014 |
Chemistry |
pmid:25346489
|
Taft F et al. |
Combined muta- and semisynthesis: a powerful synthetic hybrid approach to access target specific antitumor agents based on ansamitocin P3. |
2012 |
Chemistry |
pmid:22170289
|
Wu Y et al. |
N-methylation of the amide bond by methyltransferase asm10 in ansamitocin biosynthesis. |
2011 |
Chembiochem |
pmid:21681880
|
Harmrolfs K et al. |
Cyclization of synthetic seco-proansamitocins to ansamitocin macrolactams by Actinosynnema pretiosum as biocatalyst. |
2010 |
Chembiochem |
pmid:21077088
|
Taft F et al. |
Highly active ansamitocin derivatives: mutasynthesis using an AHBA-blocked mutant. |
2008 |
Chembiochem |
pmid:18381586
|
Kubota T et al. |
Determination of the cryptic stereochemistry of the first PKS chain-extension step in ansamitocin biosynthesis by Actinosynnema pretiosum. |
2006 |
Chembiochem |
pmid:16927319
|
Knobloch T et al. |
Mutational biosynthesis of ansamitocin antibiotics: a diversity-oriented approach to exploit biosynthetic flexibility. |
2011 |
Chembiochem |
pmid:22238146
|
Akimoto H et al. |
Chemical modification of ansamitocins. II. Synthesis of 3-epimaytansionoids via 3-maytansinones. |
1984 |
Chem. Pharm. Bull. |
pmid:6437689
|
Kawai A et al. |
Chemical modification of ansamitocins. III. Synthesis and biological effects of 3-acyl esters of maytansinol. |
1984 |
Chem. Pharm. Bull. |
pmid:6441645
|
Cassady JM et al. |
Recent developments in the maytansinoid antitumor agents. |
2004 |
Chem. Pharm. Bull. |
pmid:14709862
|
Wang H et al. |
Albumin nanoparticle encapsulation of potent cytotoxic therapeutics shows sustained drug release and alleviates cancer drug toxicity. |
2017 |
Chem. Commun. (Camb.) |
pmid:28195282
|
Fishkin N et al. |
A novel pathway for maytansinoid release from thioether linked antibody-drug conjugates (ADCs) under oxidative conditions. |
2011 |
Chem. Commun. (Camb.) |
pmid:21874179
|
Zhao P et al. |
Amide N-glycosylation by Asm25, an N-glycosyltransferase of ansamitocins. |
2008 |
Chem. Biol. |
pmid:18721757
|
Li Y et al. |
Dual carbamoylations on the polyketide and glycosyl moiety by asm21 result in extended ansamitocin biosynthesis. |
2011 |
Chem. Biol. |
pmid:22195559
|
David B et al. |
Rhazinilam mimics the cellular effects of taxol by different mechanisms of action. |
1994 |
Cell Motil. Cytoskeleton |
pmid:7954858
|
Diessner J et al. |
Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1). |
2014 |
Cell Death Dis |
pmid:24675467
|
Stebbings H and van Bueren J |
Stability of microtubules from insect ovarioles. |
1981 |
Cell Biol. Int. Rep. |
pmid:7273149
|
Issell BF and Crooke ST |
Maytansine. |
1978 |
Cancer Treat. Rev. |
pmid:367597
|
Kümler I et al. |
A systematic review of dual targeting in HER2-positive breast cancer. |
2014 |
Cancer Treat. Rev. |
pmid:24080156
|
Yan M et al. |
HER2 aberrations in cancer: implications for therapy. |
2014 |
Cancer Treat. Rev. |
pmid:24656976
|
Carneiro BA et al. |
Emerging therapeutic targets in bladder cancer. |
2015 |
Cancer Treat. Rev. |
pmid:25498841
|
Neidhart JA et al. |
Minimal single-agent activity of maytansine in refractory breast cancer: a Southwest Oncology Group study. |
1980 Apr-May |
Cancer Treat Rep |
pmid:7427953
|